

Vabysmo™ (faricimab-svoa intravitreal)

When requesting Vabysmo™ (faricimab-svoa intravitreal injection) the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or one of the off-label compendial uses and meet the specific coverage guidelines for the covered indication.

FDA-Approved Indications

Vabysmo is indicated for the treatment of patients with:

- Neovascular (wet) age-related macular degeneration (nAMD)
- Diabetic macular edema (DME)
- Macular edema following retinal vein occlusion (RVO)

Approved Off-Label Compendial Uses

- Other neovascular diseases of the eye (e.g., angioid streaks, iris neovascularization, neovascular glaucoma, pachychoroid neovasculopathy, polypoidal choroidal vasculopathy, and presumed ocular histoplasmosis syndrome).

Coverage Guidelines

Diabetic macular edema (DME), Neovascular (wet) age-related macular degeneration (nAMD), Macular edema following retinal vein occlusion (RVO), and other neovascular diseases of the eye

The individual must meet the following criteria:

- Vabysmo is administered by or under the supervision of an ophthalmologist

Approval duration: 12 months

Dosing Recommendations

Diabetic macular edema (DME), Neovascular (wet) age-related macular degeneration (nAMD), Macular edema following retinal vein occlusion (RVO), and other neovascular diseases of the eye

The recommended dose is 6 mg administered by intravitreal injection not more frequently than once every 4 weeks (approximately every 28 ± 7 days) for each eye being treated.

References

1. Vabysmo™ intravitreal injection [prescribing information]. South San Francisco, CA: Genentech/Roche; July 2024.
2. Hang A, Feldman S, Amin AP, et al. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. *Pharmaceuticals*. 2023;16:1140. Doi.org/10.3390/ph16081140.